Clinical trials: Antibody-mediated Rejection
Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second leading cause of late mortality after heart transplantation.
- Trial name
- NCT01848301
- Testing
- Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gladwin, Mark, MD
Late Rejection of Renal Transplant, Antibody-mediated Rejection
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
Late antibody-mediated rejection (AMR) after kidney transplantation is defined as a separate rejection entity. So far, no appropriate treatment has been established for this rejection type.
- Trial name
- BORTEJECT (NCT01873157)
- Testing
- Bortezomib
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- Medical University of Vienna
Antibody-mediated Rejection, Autoimmune Reaction Mediated by Immune Complex
Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange
Therapeutic plasma exchange (TPE) is an established treatment modality for the acute removal of pathophysiological relevant mediators in various diseases.
- Trial name
- NCT02533596
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Hannover Medical School